TABLE 2.
ALT (U/l) |
AST (U/l) |
|||
Time (h) | WT | Gal-3−/− | WT | Gal-3−/− |
CTL | 32.1 ± 2.6 | 45.4 ± 7.2 | 60.6 ± 5.6 | 82.5 ± 10.6 |
6 | 7797.0 ± 508.1a | 6363.1 ± 1266.9 | 7473.0 ± 481.8a | 7711.1 ±1917.4a |
24 | 10,905.8 ± 825.5a | 7673.6 ± 1022.9a,b | 6391.1 ± 911.4a | 3908.2 ± 723.6a |
48 | 1194.0 ± 126.1a | 454.2 ± 53.5b | 522.9 ± 51.8a | 265.7 ± 26.5b |
72 | 247.6 ± 41.4 | 116.6 ± 15.1b | 261.4 ± 29.3 | 93.8 ± 15.4b |
Notes. ALT, alanine aminotransferase; AST, aspartate aminotransferase. WT and Gal-3−/− mice were treated with 300 mg/kg APAP or PBS control (CTL). Sera were collected 6–72 h later and analyzed for ALT and AST. Data are expressed as mean ± SE (n = 5–12 mice).
Significantly different (p < 0.05) from CTL.
Significantly different from WT.